We are an innovative biopharmaceutical start-up dedicated to developing cutting-edge, personalized treatments for cancer and chronic viral diseases. Our lead product is designed to target not only cancer and virus-infected cells, but also chemotherapy-resistant cancer stem cells and viral reservoirs, which are believed to drive disease recurrence. This therapeutic approach stands out for its enhanced anti-tumor efficacy and the absence of severe side effects, offering a unique and transformative solution for patients. The company is now part of the Takeda Pharmaceuticals portfolio. In addition to our product development efforts, we now offer expert consultancy services. Leveraging our deep knowledge and experience in biopharmaceutical innovation, we provide strategic guidance to companies and organizations in the healthcare and life sciences sectors, helping them navigate complex challenges and accelerate the development of novel therapeutics.
| Website | http://www.lymphact.com |
| Revenue | $3.8 million |
| Employees | View employees |
| Founded | 2013 |
| Technologies |
JavaScript
,
HTML
,
PHP
+23 more
(view full list)
|
| Industry | Biotechnology, Biotechnology Research, Biopharma, Cellular Therapies, Pharmaceuticals, Immunotherapies, Healthcare, Health Care, Oncology, Science and Engineering, Immunology, Pharmaceutical |
| Competitors | LympheDIVAs, Juzo - Julius Zorn GmbH, SIGVARIS GROUP, medi USA, LymphaTouch, Compressor Systems, Inc., Swelling Solutions, Medela, Aircast Incorporated, Arjo +16 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Lymphact employee's phone or email?
Lymphact Questions
The Lymphact annual revenue was $3.8 million in 2026.
Lymphact is based in Lisbon, Lisbon.
The NAICS codes for Lymphact are [3254, 325, 32].
The SIC codes for Lymphact are [283, 28].
Related Companies
